Key questions to be discussed at iwCLL 2017: cancer genetics, immunology and categorizing patients
What does the CLL forum data tell us?
Drug–drug interactions & the potential impact on toxicity levels in patients with B-cell malignancy
The role of blinatumomab in ALL
Can the dream of affordable cancer care come true?